The influence of intermittent fasting on body metrics, lipid profile, and physical performance in young and middle-aged men.

Nutr HealthOct 15, 2025 (epub)

Maha Gasmi, Aymen Hawani, Anis Ben Chikha et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial assessed five months of intermittent fasting, four days per week, in 40 active men aged 23–28 or 46–59 years. Compared with control groups, both fasting groups had significant reductions in weight, BMI and fat-free mass; weight showed a time-by-group interaction (p = 0.017). Total cholesterol and HDL also decreased in both age groups, while LDL decreased significantly only in younger men. Triglycerides and performance on a running-based anaerobic sprint test were not significantly affected. Body fat percentage did not change significantly.

Key findings

  • Weight decreased in both fasting groups versus controls; the time-by-group interaction was significant (p = 0.017).
  • BMI and fat-free mass decreased in both fasting groups; body fat percentage showed no significant change.
  • Total cholesterol and HDL decreased in both fasting groups; LDL decreased significantly only in the young group (p = 0.041).
  • Intermittent fasting did not significantly affect triglyceride levels or physical performance.

Why it matters

The findings suggest that, in active young and middle-aged men, intermittent fasting may alter weight and selected lipid measures without measurable improvement or decline in the tested anaerobic performance. The reductions in fat-free mass and HDL are relevant when interpreting the overall metabolic response; the study does not establish longer-term effects or broader applicability.

What to keep in mind

The trial included only 40 active men in two age groups and assessed a five-month intervention; applicability to other populations and longer-term outcomes is uncertain.

Source

Published in Nutr Health. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.